Sports
Infinitopes to Showcase Breakthroughs on Cancer Vaccine Development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial
Infinitopes' lead vaccine candidate ITOP1 is a novel, precision targeted, immunologically durable, "off-the-shelf" cancer vaccine, designed to save lives by preventing disease recurrence in first-line patients with surgically resectable cancers Infin
By: prnewswire_apac
- Nov 08 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS